Biotech takes on superbugs

By Paul Armstrong
Updated: 00:00 BST, 9 August 2002

?

BRITISH Biotech's 押し進める to develop a new 世代 of 抗生物質s while not running out of cash has led it to strike a 研究 共同の 投機・賭ける with US 相当するもの GeneSoft.

The 取引，協定 will see GeneSoft use its 麻薬 開発 技術s to 実験（する） 抗生物質s which British Biotech believes will 反対する the sorts of s uperbugs 契約d in hospitals.

財政／金融 director Tony Weir said British Biotech, which had £50m in the kitty at the end of April, would 削減（する） its 年次の cash 燃やす 率 from £18m to £15m by splitting the 開発 costs 平等に with GeneSoft. But he said British Biotech, which will get $5m (£3.3m) and a 3.45% 火刑／賭ける in GeneSoft as an 初期の 支払い（額）, would 保持する the 商業の 権利s to the 麻薬s.

The first of the 抗生物質s will を受ける 臨床の 裁判，公判s in October, though the 広範囲にわたる 実験（する）s and need to 勝利，勝つ regulatory 是認 means they would not be for sale for five years.